Celgene announced  the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene’s proprietary IMiD medications, Revlimid (lenalidomide) and Imnovid (pomalidomide)....